RxDoctor Payments Data

Saba Shaikh

Medical Oncology · San Antonio, TXNPI 1598110801

Payments from drug & device makers

What this record shows

This record is dominated by education: $100 of the $132 with a category attached, or 75.6%. Genentech USA, Inc. accounts for 75.6% of it on its own, with 2 other manufacturers making up the rest. That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.

$132in general payments, 2019–2025

Across 3 payments — averaging $44.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$100
  • Lilly USA, LLC$18
  • Tempus AI, Inc$15
$144,430in research payments, 2019–2025

Across 2 payments — averaging $72,215 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$144K

What the payments were for

  • Food & beverage$3224%
  • Education$10076%

General payments by program year

19
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech USA, Inc.1$100
Lilly USA, LLC1$18
Tempus AI, Inc1$15

How this compares

$132 in reported general payments places this provider in the 10th percentile of 495 medical oncology providers in Texas.

See all medical oncology providers in Texas →

Medicare billing

Part B allowed, 2024
$547,122
Medicare patients
135
Services billed
18,976

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Anastrozole50$1,108
Letrozole13$308

Paid to pharmacies, not to this prescriber.

Other medical oncology in San Antonio

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →